The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Analyst Jason McCarthy from Maxim Group reiterated a Buy rating on Gain Therapeutics (GANX – Research Report) and keeping the price ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 9.81% of ...

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today and set a price ...

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...

The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - (SIX/NASDAQ: ADXN), a clinical-stage ...

Buyers returned to the stock market today after the Federal Reserve decided to cut short-term interest rates by half a point ...

Shares of Applied Therapeutics (NASDAQ: APLT) had skyrocketed 70.5% as of 10:43 a.m. ET on Wednesday. The huge gain came after the U.S. Food and Drug Administration (FDA) told the company that an ...